The proportion of people with heart failure receiving optimal therapy increased significantly with expansion of this initiative within a general cardiology practice.

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those ...

An international team of researchers at the University of Manchester, Baylor College of Medicine and collaborating institutions has discovered a natural mechanism that protects the heart from heart ...

The Ohio State University Wexner Medical Center is the first site in the U.S. to enroll a patient in an international trial ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Panelists discuss how heart failure classification involves HFrEF vs HFpEF distinctions and staging systems (A through D), with the greatest prevention opportunities existing in early stages A and B, ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, ...

Results from the Phase 3 VICTOR trial and a pooled analysis of the VICTOR and VICTORIA trials were presented today at the ESC Congress 2025 and simultaneously published in The Lancet Merck (NYSE: MRK) ...

The American College of Cardiology is launching a new program to educate clinicians on the latest advances, medications and ...

Heart failure with preserved ejection fraction (known as HFpEF), is the most common kind of heart failure, affecting millions globally. The heart still pumps, it just can't relax and fill ...

Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person's internal fat tissue, according to the Adipokine Hypothesis, a new way of ...